Skip to main content

The Effect of the PPAR- Agonist Rosiglitazone on Neuroblastoma SK-N-SH Cells in a Metastatic Xenograft Mouse Model

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


Rosiglitazone, a peroxisome proliferator activated receptor- (PPAR-) agonist used in clinical practice to treat type 2 diabetes, has been shown to inhibit neuroblastoma cell proliferation in vitro. In the present study, SK-N-SH neuroblastoma cells were subcutaneously injected into SCID mice and their growth and metastatic behavior under the treatment with rosiglitazone was analyzed. Therapeutic effects were evaluated comparing primary tumor weight, cell proliferation, apoptosis, and number of pulmonary metastasis. Rosiglitazone significantly decreased cell proliferation of the SK-N-SH neuroblastomas from 57.0% in the solvent control to 45.0% and 47.0% in the two treatment groups, respectively. However, primary tumor weight, apoptosis, and metastasis were not considerably influenced. These results indicate that the PPAR- agonist rosiglitazone has only slight antitumor effects on SK-N-SH neuroblastoma growth in vivo in contrast to in vitro.

Keywords: Neuroblastoma; PPAR- agonists; Rosiglitazone; SCID mouse

Document Type: Research Article


Publication date: August 1, 2010


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more